MARKET

SABSW

SABSW

SAB BIOTHERAPEUTICS INC
NASDAQ
0.0399
+0.0031
+8.42%
Opening 10:18 02/10 EST
OPEN
0.0399
PREV CLOSE
0.0368
HIGH
0.0399
LOW
0.0399
VOLUME
750
TURNOVER
--
52 WEEK HIGH
0.1800
52 WEEK LOW
0.0205
MARKET CAP
--
P/E (TTM)
-0.0142
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SABSW last week (0202-0206)?
Weekly Report · 1d ago
SAB Biotherapeutics to Present at Guggenheim Biotech Summit and Oppenheimer Healthcare Conference
Reuters · 6d ago
Weekly Report: what happened at SABSW last week (0126-0130)?
Weekly Report · 02/02 09:54
Weekly Report: what happened at SABSW last week (0119-0123)?
Weekly Report · 01/26 09:54
Weekly Report: what happened at SABSW last week (0112-0116)?
Weekly Report · 01/19 09:58
Weekly Report: what happened at SABSW last week (0105-0109)?
Weekly Report · 01/12 09:57
SAB Biotherapeutics Inc. Files Initial Statement of Beneficial Ownership for Director David Zaccardelli
Reuters · 01/07 21:35
SAB Biotherapeutics Names David Zaccardelli as Board Chair and Rita Jain as Director
Reuters · 01/07 13:00
More
About SABSW
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.

Webull offers SAB Biotherapeutics Inc stock information, including NASDAQ: SABSW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SABSW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SABSW stock methods without spending real money on the virtual paper trading platform.